0001104659-24-006396.txt : 20240125 0001104659-24-006396.hdr.sgml : 20240125 20240125060210 ACCESSION NUMBER: 0001104659-24-006396 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240122 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Francomano Robert CENTRAL INDEX KEY: 0001797467 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33958 FILM NUMBER: 24558456 MAIL ADDRESS: STREET 1: C/O STEMLINE THERAPEUTICS, INC. STREET 2: 750 LEXINGTON AVENUE, 11TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 4 1 tm243935-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-22 0 0001390478 SELLAS Life Sciences Group, Inc. SLS 0001797467 Francomano Robert C/O SELLAS LIFE SCIENCES GROUP, INC., 7 TIMES SQUARE, SUITE 2503 NEW YORK NY 10036 0 1 0 0 Chief Commercial Officer 0 Common Stock 2024-01-22 4 A 0 20000 0.00 A 40918 D Stock Option (Right to Buy) 0.5195 2024-01-22 4 A 0 30000 0 A 2034-01-22 Common Stock 30000 30000 D The Reporting Person received an award of 20,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. /s/ Robert Francomano 2024-01-24